Fichorova RN

No ORCID on file · 4 papers in corpus
2021
Epidemiologic and biologic correlates of serum HE4 and CA125 in women from the National Health and Nutritional Survey (NHANES).
Gynecologic Oncology ·doi:10.1016/j.ygyno.2021.01.011

ObjectivesIn women with ovarian cancer, tumor features largely determine serum HE4 and CA125 levels, but non-tumor factors may also influence levels and be better understood by studying determinants in a well-characterized sample of women w…

2019
Development and validation of circulating CA125 prediction models in postmenopausal women.
Journal of ovarian research ·doi:10.1186/s13048-019-0591-4

BackgroundCancer Antigen 125 (CA125) is currently the best available ovarian cancer screening biomarker. However, CA125 has been limited by low sensitivity and specificity in part due to normal variation between individuals. Personal charac…

other 2019
Predicting Circulating CA125 Levels among Healthy Premenopausal Women
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology ·doi:10.1158/1055-9965.EPI-18-1120

BACKGROUND: Cancer antigen 125 (CA125) is the most promising ovarian cancer screening biomarker to date. Multiple studies reported CA125 levels vary by personal characteristics, which could inform personalized CA125 thresholds. However, thi…

2013
Puerperal mastitis: a reproductive event of importance affecting anti-mucin antibody levels and ovarian cancer risk.
Cancer causes & control : CCC ·doi:10.1007/s10552-013-0266-1

PurposeTest the hypothesis that puerperal mastitis may alter immunity related to the mucin (MUC) family of glycoproteins and lower risk of ovarian cancer.MethodsIn two case-control studies conducted in New England between 1998 and 2008, we …